Related Experiment Videos
[Acromegaly]
Mai Christiansen Arlien-Søborg1, Anne Mohr Drewes, Mogens Pfeiffer-Jensen
1mas@clin.au.dk.
Ugeskrift for Laeger
|December 7, 2018
Summary
Acromegaly, caused by excess growth hormone and IGF-1, leads to disabling symptoms and comorbidities. Early diagnosis and treatment are crucial for managing this rare condition and reducing patient morbidity.
Area of Science:
- Endocrinology
- Rare Diseases
- Medical Diagnostics
Background:
- Acromegaly results from sustained excess of growth hormone (GH) and insulin-like growth factor 1 (IGF-1).
- The condition causes excessive somatic growth, comorbidities, and potential optic nerve compression or hypopituitarism from adenomas.
- Disease progression is insidious, with typical diagnostic delays of 5-10 years, increasing morbidity.
Purpose of the Study:
- To summarize the key aspects of acromegaly, including its pathophysiology, clinical manifestations, diagnostic challenges, and treatment availability.
Main Methods:
- Literature review of acromegaly pathophysiology, clinical presentation, diagnostic delays, and treatment outcomes.
- Synthesis of information on the impact of growth hormone and IGF-1 excess.
- Analysis of the morbidity associated with delayed diagnosis.
Main Results:
- Acromegaly is characterized by elevated GH and IGF-1, leading to significant somatic growth and diverse comorbidities.
- Diagnostic delays are common, contributing to increased patient morbidity during the pre-diagnostic period.
- Effective treatments are available following diagnosis.
Conclusions:
- Acromegaly is a serious condition requiring timely diagnosis and management.
- Understanding the long-term effects of GH/IGF-1 excess is vital for patient care.
- Prompt diagnosis significantly improves outcomes and reduces morbidity associated with acromegaly.